Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C25H31ClF2O5 |
Molecular Weight | 484.96 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 9 / 9 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]12C[C@H](C)[C@](OC(=O)CC)(C(=O)CCl)[C@@]1(C)C[C@H](O)[C@@]3(F)[C@@]2([H])C[C@H](F)C4=CC(=O)C=C[C@]34C
InChI
InChIKey=BDSYKGHYMJNPAB-LICBFIPMSA-N
InChI=1S/C25H31ClF2O5/c1-5-21(32)33-25(20(31)12-26)13(2)8-15-16-10-18(27)17-9-14(29)6-7-22(17,3)24(16,28)19(30)11-23(15,25)4/h6-7,9,13,15-16,18-19,30H,5,8,10-12H2,1-4H3/t13-,15-,16-,18-,19-,22-,23-,24-,25-/m0/s1
Molecular Formula | C25H31ClF2O5 |
Molecular Weight | 484.96 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 9 / 9 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Approval Year
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:33:49 UTC 2023
by
admin
on
Fri Dec 15 15:33:49 UTC 2023
|
Record UNII |
91A0K1TY3Z
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C521
Created by
admin on Fri Dec 15 15:33:49 UTC 2023 , Edited by admin on Fri Dec 15 15:33:49 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
m5899
Created by
admin on Fri Dec 15 15:33:49 UTC 2023 , Edited by admin on Fri Dec 15 15:33:49 UTC 2023
|
PRIMARY | Merck Index | ||
|
1349
Created by
admin on Fri Dec 15 15:33:49 UTC 2023 , Edited by admin on Fri Dec 15 15:33:49 UTC 2023
|
PRIMARY | |||
|
Ulobetasol propionate
Created by
admin on Fri Dec 15 15:33:49 UTC 2023 , Edited by admin on Fri Dec 15 15:33:49 UTC 2023
|
PRIMARY | |||
|
1302906
Created by
admin on Fri Dec 15 15:33:49 UTC 2023 , Edited by admin on Fri Dec 15 15:33:49 UTC 2023
|
PRIMARY | |||
|
100000084781
Created by
admin on Fri Dec 15 15:33:49 UTC 2023 , Edited by admin on Fri Dec 15 15:33:49 UTC 2023
|
PRIMARY | |||
|
91A0K1TY3Z
Created by
admin on Fri Dec 15 15:33:49 UTC 2023 , Edited by admin on Fri Dec 15 15:33:49 UTC 2023
|
PRIMARY | |||
|
66852-54-8
Created by
admin on Fri Dec 15 15:33:49 UTC 2023 , Edited by admin on Fri Dec 15 15:33:49 UTC 2023
|
PRIMARY | |||
|
DB00596
Created by
admin on Fri Dec 15 15:33:49 UTC 2023 , Edited by admin on Fri Dec 15 15:33:49 UTC 2023
|
PRIMARY | |||
|
CHEMBL1200908
Created by
admin on Fri Dec 15 15:33:49 UTC 2023 , Edited by admin on Fri Dec 15 15:33:49 UTC 2023
|
PRIMARY | |||
|
BB-2
Created by
admin on Fri Dec 15 15:33:49 UTC 2023 , Edited by admin on Fri Dec 15 15:33:49 UTC 2023
|
PRIMARY | |||
|
SUB05030MIG
Created by
admin on Fri Dec 15 15:33:49 UTC 2023 , Edited by admin on Fri Dec 15 15:33:49 UTC 2023
|
PRIMARY | |||
|
6918178
Created by
admin on Fri Dec 15 15:33:49 UTC 2023 , Edited by admin on Fri Dec 15 15:33:49 UTC 2023
|
PRIMARY | |||
|
DTXSID6046636
Created by
admin on Fri Dec 15 15:33:49 UTC 2023 , Edited by admin on Fri Dec 15 15:33:49 UTC 2023
|
PRIMARY | |||
|
91A0K1TY3Z
Created by
admin on Fri Dec 15 15:33:49 UTC 2023 , Edited by admin on Fri Dec 15 15:33:49 UTC 2023
|
PRIMARY | |||
|
C47553
Created by
admin on Fri Dec 15 15:33:49 UTC 2023 , Edited by admin on Fri Dec 15 15:33:49 UTC 2023
|
PRIMARY | |||
|
45318
Created by
admin on Fri Dec 15 15:33:49 UTC 2023 , Edited by admin on Fri Dec 15 15:33:49 UTC 2023
|
PRIMARY | RxNorm |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TARGET -> AGONIST |
Halobetasol propionate is thought to act by the induction of phospholipase A2 inhibitory proteins, collectively called lipocortins.The initial interaction, however, is due to the drug binding to the cytosolic glucocorticoid receptor. After binding the receptor the newly formed receptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes.
|
||
|
BASIS OF STRENGTH->SUBSTANCE |
ASSAY (HPLC)
USP
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|